SCHEMBL339395

SCHEMBL339395

CC(=O)NC(Cc1ccc(-c2ccccc2)cc1)(C(=O)O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
RECQL P46063 1/20 0.56
MMP8 P22894 1/20 0.52
LMNA P02545 3/20 0.44
ABCC4 O15439 1/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
PTGS1 P23219 1/20 0.44
HTT P42858 1/20 0.44
ACACB O00763 1/20 0.43
FFAR1 O14842 1/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MMP12 P39900 1/20 0.41
MME P08473 2/20 0.41
ACE P12821 2/20 0.41
ACE2 Q9BYF1 2/20 0.41
CPA1 P15085 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28168069 0.90 ALDH1A1 (0.67) ALDH1A1RECQLMMP8LMNAMAPT
SCHEMBL340184 0.84 KMT2A (0.49) ALDH1A1RECQLLMNAABCC4GAA
SCHEMBL2780432 0.83 ALDH1A1 (0.51) ALDH1A1RECQLMMP8LMNATSHR
SCHEMBL6051878 0.83 ALDH1A1 (0.51) ALDH1A1RECQLMMP8LMNATSHR
SCHEMBL20195079 0.83 LMNA (0.47) ALDH1A1LMNAABCC4GAATSHR
SCHEMBL6051898 0.82 RECQL (0.50) ALDH1A1RECQLMMP8TSHRACACB
SCHEMBL6051877 0.82 ALDH1A1 (0.50) ALDH1A1RECQLMMP8LMNAACACB
SCHEMBL340407 0.82 L3MBTL1 (0.46) ALDH1A1RECQLFFAR1SMN1; SMN2MEN1
SCHEMBL4065071 0.79 ALDH1A1 (0.50) ALDH1A1RECQLMMP8GAATSHR
SCHEMBL6361552 0.78 ALDH1A1 (0.47) ALDH1A1RECQLMMP8HTTACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624163-B2 Process for preparing intermediates useful in the manufacture of NEP inhibitors NOVARTIS AG (CH) 2017-04-18 US disclosed
US-9624163-B2 Process for preparing intermediates useful in the manufacture of NEP inhibitors NOVARTIS AG (CH) 2017-04-18 US disclosed
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
US-9181175-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2015-11-10 US disclosed
US-20150210632-A1 NEW PROCESS NOVARTIS AG (CH) 2015-07-30 US disclosed
EP-2387558-B1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2014-08-27 EP disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2014-06-26 US disclosed
US-8703990-B2 Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) 2014-04-22 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID NOVARTIS AG (CH) 2012-01-19 US disclosed
EP-2387558-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) 2011-11-23 EP disclosed
US-20110253230-A1 Temperature Sensitive Valve Having Shape Memory Actuator OMNITEK PARTNERS LLC (US) 2011-10-20 US disclosed
WO-2010081410-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) 2010-07-22 WO disclosed
CN-101774941-A Method for preparing and splitting 2-acyl amino-3-biphenylyl propionic acid ZHEJIANG JIUZHOU PHARMACEUTICA 2010-07-14 CN disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210632-A1 NEW PROCESS MME, DNPEP, ACE ALDH1A1 389/4885RECQL 4788/4885MMP8 2305/4885
US-20140179947-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 ALDH1A1 1079/4885RECQL 4803/4885MMP8 803/4885
US-20120016151-A1 PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID DNPEP, MME, DPP7 ALDH1A1 1079/4885RECQL 4803/4885MMP8 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.